Global Targeted Protein Degradation Market, By Type (Degronimids, Immunomodulatory Drugs (IMiDs), Proteolysis-targeting chimeric molecules (PROTACs), Sudden acquired retinal degeneration syndrome (SARDs), Selective Estrogen Receptor Degraders (SERDs), Specific bromodomain and extra-terminal domain (BET) and Deubiquitinases (DUB) Inhibitors), Therapeutic Area (Inflammatory Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, Other Therapeutic Areas), Route of Administration (Oral, Intravenous, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Targeted proteolysis (TPD) has occurred as a fresh and advanced chemical tool and beneficial modality. By choosing a proteolytic pathway, TPD encourages the whole consent of protein molecules inside or outside the cell. While inventive proteolysis-targeting chimera (PROTAC) technology and molecular adhesives are interrupting the ubiquitin-proteasome system, original modalities hire autophagy or endo-lysosomal pathways.
Data Bridge Market Research analyses that the targeted protein degradation market which was USD 103.31 million in 2021, would rocket up to USD 224.70 million by 2029, and is expected to undergo a CAGR of 10.20% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Targeted protein degradation is innovatory pharmacological perception that grants practical drug development chances and is expected to announce a new paradigm in modern therapeutic interventions. Due to various reasons, conventional drugs/therapies have been partial in terms of their competence to target certain proteins of pathological significance.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Degronimids, Immunomodulatory Drugs (IMiDs), Proteolysis-targeting chimeric molecules (PROTACs), Sudden acquired retinal degeneration syndrome (SARDs), Selective Estrogen Receptor Degraders (SERDs), Specific bromodomain and extra-terminal domain (BET) and Deubiquitinases (DUB) Inhibitors), Therapeutic Area (Inflammatory Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, Other Therapeutic Areas), Route of Administration (Oral, Intravenous, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Eli Lilly and Company (U.S), Gilead Sciences, Inc. (U.S), GSK plc (U.K), Merck KGaA (Germany), Mission Therapeutics (U.K), Novartis AG (Switzerland), Pfizer Inc. (U.S), Aurigene Discovery Technologies (India), Avista Pharma Solutions (U.S), Barbara Ann Karmanos Cancer Center (U.S), 5AM Venture Management LLC (U.S), AbbVie Inc (U.S), Almac Group (U.K), Amgen Inc. (U.S), Bayer AG (Germany), Biogen (U.S), C4 Therapeutics Inc. (U.S), Cosmo Bio USA (U.S), Mission Therapeutics (U.S), Roivant Sciences Ltd. (Switzerland)
|
|
Market Opportunities
|
|
Targeted Protein Degradation Market Dynamics
Drivers
- Increasing adoption of advanced technology
In the forecast period of 2022-2029, therapeutic methods, rising usages of technology for epichaperome inhibitors, hydrophobic tags, lysosome targeting chimaeras, and others, as well as an increasing demand for protein degradation for drug discovery strategy to treat diseases, are expected to boost the growth of the targeted protein degradation market. The expanding number of research and development activities, on the other hand, will provide enormous chances for the targeted protein degradation market to grow throughout the forecast period.
- Increasing demand for immunoassay to diagnose and detect microorganism based infections
Constantly growing frequency of chronic disease conditions such as cancer and autoimmune disorders, changing lifestyle, increasing habit of smoking and drinking, and increasing spending on healthcare are also accelerating the market growth.
- Increasing awareness among the people regarding the benefits of protein degradation
Proteins are rapidly degraded in response to a precise signals, if alternative apparatus for the guideline of intracellular enzyme action. In accumulation, faulty or damaged proteins are recognized and rapidly degraded within cells, thereby removing the significances of mistakes made during protein synthesis. It will also increase the market growth.
- Increasing demand for protein degradation for drug discovery strategy to treat diseases
Protein degradation pathways play an essential role in maintaining cellular homeostasis and regulating various cellular processes. And over the past decade they have been the topic of intense research.
Opportunities
Growing acceptance of advanced technology and beneficial methods, increasing practices of technology for epichaperome inhibitors, hydrophobic tags, lysosome aiming chimeras, and others, increasing demand of protein deprivation for drug discovery approach to treat diseases which will likely to improve the growth of the targeted protein degradation market in the forecast period of 2020-2029. On the other hand, increasing quantity of research and development activities will further bring immense chances for developing the targeted protein degradation market in the above mentioned forecast period.
Restraints/Challenges
- Complex structure and the interactions between the E3 ligase and the target protein
Moreover, drugs designed based on this moderately original concept, have been shown to validate a remarkable level of selectivity, oral bioavailability and differentiated pharmacology as compared to traditional enzyme inhibitors. Protein degraders regularize organic ways by selectively downregulating a target protein by degrading them and this process has been shown to be vigorous.
This targeted protein degradation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the targeted protein degradation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Targeted Protein Degradation Market
Targeted protein degradation has been applied to numerous disease domains and we propose that it could be amazingly beneficial to tackle the current pandemic. Fully seeing the profitable change by this health crisis, Oral accounting for the targeted protein degradation global market in 2021, is projected to value USD million by 2028, growing at a revised CAGR in the post-COVID-19 period.
Global Targeted Protein Degradation Market Scope
The targeted protein degradation market is segmented on the basis of type, application, therapeutic areas and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Degronimids
- Immunomodulatory Drugs (IMiDs)
- Proteolysis-targeting chimeric molecules (PROTACs)
- Sudden acquired retinal degeneration syndrome (SARDs)
- Selective Estrogen Receptor Degraders (SERDs)
- Specific bromodomain
- Extra-terminal domain (BET)
- Deubiquitinases (DUB) Inhibitors
Therapeutic Area
-
Inflammatory Disorders
-
Neurological Disorders
-
Oncological Disorders
-
Respiratory Disorders
-
Other
Route of Administration
- Oral
- Intravenous
- Others
Application
- Hospital
- Research Institute
Therapeutic Area
- Inflammatory Disorders
- Neurological Disorders
- Oncological Disorders
- Respiratory Disorders
- Other Therapeutic Areas
Targeted Protein Degradation Market Regional Analysis/Insights
The targeted protein degradation market is analysed and market size insights and trends are provided by country, type, price range, application and end user as referenced above.
The countries covered in the targeted protein degradation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the targeted protein degradation market because of the increasing number of research and development activities.
Due to an increase in government initiatives to promote awareness, an increase in medical tourism, growing research activities in the region, the availability of massive untapped markets, a large population pool, and the growing demand for quality healthcare in the region, Asia-Pacific is expected to see significant growth during the forecast period of 2022 to 2029.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The targeted protein degradation market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for targeted protein degradation market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the targeted protein degradation market. The data is available for historic period 2010-2020.
Competitive Landscape and Targeted Protein Degradation Market Share Analysis
The targeted protein degradation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to targeted protein degradation market.
Some of the major players operating in the targeted protein degradation market are:
- Eli Lilly and Company (U.S)
- Gilead Sciences, Inc. (U.S)
- GSK plc (U.K)
- Merck KGaA (Germany)
- Mission Therapeutics (U.K)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S)
- Aurigene Discovery Technologies (India)
- Avista Pharma Solutions (U.S)
- Barbara Ann Karmanos Cancer Center (U.S)
- 5AM Venture Management LLC (U.S)
- AbbVie Inc (U.S)
- Almac Group (U.K)
- Amgen Inc. (U.S)
- Bayer AG (Germany)
- Biogen (U.S)
- C4 Therapeutics Inc. (U.S)
- Cosmo Bio USA (U.S)
- Mission Therapeutics (U.S)
- Roivant Sciences Ltd. (Switzerland)
SKU-